What pharmacure pharmaceutical does

PharmaCure Pharmaceutical Industries is a privately-held Egyptian pharmaceutical manufacturer founded in 1999, operating from a manufacturing facility in the 4th Industrial Zone of El Sadat City and a separate marketing and distribution center in Obour City. The company produces a multi-category generic pharmaceutical portfolio in solid dosage (tablets, coated tablets, hard gelatin capsules), liquid dosage (syrups, suspensions), purified water, and veterinary powder forms, spanning diabetes (Pharmavildamin), hypertension (Alphdopa), benign prostatic hyperplasia (Congdosin), allergies (Pharmabilast), bacterial infections (Azropharma, Oxazolide, Primoxizar), gastrointestinal disorders (Razopump, Rebamucaulc), cold symptoms (Rhinocalm), and lactation support (Herbana).

Production is conducted under cGMP and WHO compliance frameworks, with self-contained and isolated human and veterinary production lines supported by HVAC, water treatment, boiler, and compressed air utility systems. The facility holds ISO 9001:2015 (quality management), ISO 14001:2015 (environmental management), and ISO 45001:2018 (occupational health and safety) certifications, and is organized across dedicated Engineering, Quality Assurance, Quality Control, Warehouse, and Production departments. Headcount is reported at 11-50 employees.

PharmaCure operates a B2B distribution-led model, selling products through Egyptian pharmacy networks and healthcare providers, with revenue generated through one-time unit sales rather than licensing or subscription arrangements. The company markets through its website (pharmacureonline.com), its Obour City in-house marketing team, and direct outreach, and operates a Pharmacovigilance department for post-market surveillance. No revenue, funding, or external institutional ownership data is disclosed; the company appears to be founder/owner-operated with no parent or holding structure indicated.

Name

pharmacure pharmaceutical

Legal name

PharmaCureOnline

Website

https://pharmacureonline.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmaCure Pharmaceutical Industries is a privately-held Egyptian generic pharmaceutical manufacturer founded in 1999, producing cGMP- and WHO-compliant tablets, capsules, syrups, and suspensions across multiple therapeutic categories for distribution through Egyptian pharmacy networks.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Human pharmaceuticals
• Dosage forms
• CGMP compliance

Headquarters

HQ city

El Zahraa, Cairo

HQ country

Egypt

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacture and sale of pharmaceutical products including tablets, capsules, syrups, and suspensions to healthcare providers and patients through distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

PharmaCure Pharmaceutical Industries manufactures a broad portfolio of branded generic human and veterinary pharmaceutical products in multiple dosage forms, including tablets, coated tablets, hard gelatin capsules, syrups, suspensions, and powder formulations. Production takes place at a cGMP- and WHO-compliant manufacturing facility in El Sadat City, Egypt, with products distributed through pharmacy networks and healthcare providers in Egypt.

Product overview

PharmaCure Pharmaceutical Industries is an established Egyptian pharmaceutical company founded in 1999, operating as a modern pharmaceutical manufacturing facility with cGMP and WHO-compliant production. The company produces a diverse portfolio of human and veterinary pharmaceutical products across multiple dosage forms. Human products include solid dosage forms (tablets, coated tablets, hard gelatin capsules) and liquid dosage forms (syrups and suspensions). The product portfolio covers therapeutic areas including diabetes management (Pharmavildamin 50/850 and 50/1000 Tablets), allergy treatment (Pharmabilast Tablets and Syrup), cold and flu relief (Rhinocalm Tablets and Syrup), hypertension (Alphdopa Tablets), benign prostatic hyperplasia (Congdosin 4 mg and 8 mg), herbal medicine for lactation (Herbana Capsules), antibiotics (Oxazolide Tablets and Suspension, Azropharma 500 mg Tablets, Primoxizar Tablets), gastrointestinal disorders (Razopump 20 mg and 40 mg Capsules, Rebamucaulc Tablets), and general wellness supplements (Unovit Syrup). Production is supported by dedicated Engineering, Quality Assurance, Quality Control, Warehouse, and Production departments.

Differentiator

Problem solved

Functional benefit

Brands

• Congdosin: Silodosin capsules for treatment of benign prostatic hyperplasia (BPH)
• Pharmavildamin
• Herbana
• Razopump
• Azropharma
• Rebamucaulc
• Oxazolide
• Pharmabilast
• Unovit
• Rhinocalm
• Alphdopa
• Primoxizar

Products and services

• Pharmavildamin Tablets (50/850 and 50/1000) Combination tablets containing 50 mg vildagliptin with either 850 mg or 1000 mg metformin hydrochloride, used as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
• Pharmabilast Tablets and Syrup Bilastine 20 mg tablets and 2.5 mg/ml oral solution for symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.
• Rhinocalm Tablets and Syrup Combination of Paracetamol, Chlorpheniramine maleate, and Pseudoephedrine hydrochloride in tablet and syrup forms for relief of common cold symptoms.
• Alphdopa Tablets Tablet containing Methyldopa sesquihydrate 281.93 mg, used for the treatment of hypertension.
• Congdosin Capsules (4 mg and 8 mg) Hard gelatin capsules containing 4 mg or 8 mg Silodosin, used for treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
• Herbana Capsules Herbal medicine in hard gelatin capsules containing Fenugreek seed powder, Fennel fruit powder, Dill fruit powder, and Caraway fruit powder, used as a lactagogue to improve lactation.
• Oxazolide Tablets and Suspension Linezolid 600 mg tablets and 100 mg/5 ml oral suspension for treatment of susceptible strains of microorganisms in pneumonia and skin and skin structure infections.
• Azropharma 500 mg Tablets Film-coated tablets containing 500 mg Azithromycin, indicated for acute bacterial sinusitis, acute bacterial otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, skin and soft tissue infections, and uncomplicated Chlamydia trachomatis urethritis and cervicitis.
• Primoxizar Tablets Film-coated tablet containing Moxifloxacin HCl 400 mg, used for treatment of bacterial infections.
• Razopump Capsules (20 mg and 40 mg) Delayed release hard gelatin capsules containing 20 mg or 40 mg Esomeprazole, used for healing of erosive esophagitis, symptomatic GERD, and Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence.
• Rebamucaulc Tablets Film-coated tablet containing 100 mg Rebamipide, used for gastric ulcer and improvement of gastric mucosal lesions including erosion, bleeding, redness, and edema in acute gastritis and acute exacerbation of chronic gastritis.
• Unovit Syrup Syrup containing 100 mg lyophilized royal jelly per 5 ml, used for support of body functions.
• Veterinary Powder Dosage Forms Veterinary solid dosage form products in powder formulation, produced under cGMP-compliant manufacturing lines.

Quantifiable outcome

• 120% increase in turnover every six months organically
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pharmaceutical Industry PartnersminorOthersThe company mentions having partners in the pharmaceutical industry but specific partner names are not listed on the website.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical manufacturer with strong presence in Africa and other emerging markets. Comparable to PharmaCure on generic product type and therapeutic breadth, particularly relevant as a benchmark for Africa-oriented generic expansion strategies.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical company with a strong MENA manufacturing and commercial footprint. Comparable to PharmaCure as a MENA-based generic manufacturer with broad therapeutic coverage, though operating at substantially greater scale and geographic reach.

Direct peers

• Pharco Pharmaceuticals: Egypt's largest pharmaceutical manufacturer, producing generic human medicines across a wide therapeutic portfolio. Highly comparable to PharmaCure on product type, target market, and manufacturing model, with substantial scale advantage.
• Egyptian International Pharmaceutical Industries Company (EIPICO): Long-established Egyptian generic pharmaceutical manufacturer producing a broad portfolio of human generics and some veterinary products. Closely comparable to PharmaCure on product type, Egyptian market focus, and multi-dosage form manufacturing.
• EVA Pharma: One of Egypt's largest domestic pharmaceutical manufacturers producing generics across multiple therapeutic categories and dosage forms. Directly comparable to PharmaCure in product type (generic human pharmaceuticals), therapeutic breadth, and Egyptian domestic market focus, though at materially larger scale.
• Minapharm Pharmaceuticals: Egypt-based pharmaceutical manufacturer with operations in both human generics and biopharmaceuticals. Comparable to PharmaCure on Egyptian manufacturing footprint and broad generic portfolio, with additional exposure to biologics.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables for MENA markets. Comparable to PharmaCure on dosage form capabilities and regional MENA positioning, serving as a regional rather than direct Egyptian competitor.
• SPIMACO Addwaeih: Saudi Arabia's largest pharmaceutical manufacturer producing generics across multiple therapeutic areas. Comparable to PharmaCure on generic manufacturing model and MENA regional positioning, though focused primarily on the Saudi market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmacure-pharmaceutical

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pharmacure pharmaceutical